Risk of Cancer Recurrence among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies

Journal of Clinical Gastroenterology

Volumn 53, Issue 1, 2019, Pages E1-E11

  Micic, Dejan ^a   Komaki, Yuga ^a   Alavanja, Aleksandar ^b   Rubin, David T ^a   Sakuraba, Atsushi ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer; cancer recurrence; inflammatory bowel disease; tumor necrosis factor inhibitor

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR;

CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; HUMAN; MEDICAL HISTORY; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; IMMUNOPATHOLOGY; NEOPLASM; TUMOR RECURRENCE;

HUMANS; IMMUNE SYSTEM DISEASES; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; TUMOR NECROSIS FACTOR INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85025658648     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000865     Document Type: Review

References (90)

1. Raval G, Mehta P. TNF-alpha inhibitors: are they carcinogenic? Drug Healthc Patient Saf. 2010;2:241-247.
2. Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013; 369:754-762.
3. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor - a therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268-1276.
4. Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009;219:209-218.
5. Hochberg MC, Tracy JK, Hawkins-Holt M, et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003;62(suppl 2):ii13-ii16.
6. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306:864-871.
7. Zhuang L, Ma W, Cai D, et al. Associations between tumor necrosis factor-alpha polymorphisms and risk of psoriasis: a meta-analysis. PLoS One. 2013;8:e68827.
8. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
9. Filipovich AH, Mathur A, Kamat D, et al. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency. 1994;5:91-112.
10. Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunodeficiencies. J Pediatr. 1995;126:1-10.
11. De Martel C, Shiels MS, Franceschi S, et al. Cancers attributable to infections among adults with HIV in the United States. AIDS (London, England). 2015;29:2173-2181.
12. Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. Semin Oncol. 2015;42:247-257.
13. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370:59-67.
14. Reed M, Cosgrove JM, Cindrich R, et al. Ten years later: a single hospital experience with malignancy in HIV/AIDS. J Surg Oncol. 2010;102:282-286.
15. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753-762.
16. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905-913.
17. Lebrec H, Ponce R, Preston BD, et al. Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr Med Res Opin. 2015;31:557-574.
18. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68:648-653.
19. Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20:119-130.
20. Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009;60: 3180-3189.
21. Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311:2406-2413.
22. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
23. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-265.e1-3.
24. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105:501-523. Quiz 24.
25. Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013;145: 1464-1478.e1-5.
26. Annese V, Beaugerie L, Egan L, et al. European evidencebased consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9:945-965.
27. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625-639.
28. Quinn MJ, d'Onofrio A, Moller B, et al. Cancer mortality trends in the EU and acceding countries up to 2015. Ann Oncol. 2003;14:1148-1152.
29. Panic N, Leoncini E, De Belvis G, et al. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One. 2013;8:e83138.
30. Williams CJM, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447-458.
31. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605.
32. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37: 1148-1157.
33. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50: 1088-1101.
34. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315: 629-634.
35. Dixon W, Watson K, Lunt M, et al. The influence of anti-TNF therapy upon cancer incidence in patients with rheumatoid arthritis (RA) who have had prior malignancy: results from the BSRBR. Rheumatology. 2009;48:I137-I138.
36. Dixon WG, Watson KD, Lunt M, et al. The influence of anti-TNF therapy upon cancer incidence in patients with rheumatoid arthritis (RA) who have had prior malignancy: results from the BSRBR. Arthritis Rheum. 2008;58:S638-S639.
37. Dixon WG, Watson KD, Lunt M, et al. Influence of antitumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2010;62:755-763.
38. Scott F, Mamtani R, Brensinger C, et al. The risk of a second non-melanoma skin cancer with thiopurine and anti-TNF use in inflammatory bowel disease. Am J Gastroenterol. 2014; 109:S493-S494.
39. Scott FI,Mamtani R, Brensinger C, et al. Risk of recurrent nonmelanoma skin cancer with methotrexate and anti-TNF use in rheumatoid arthritis. Arthritis Rheumatol. 2014;66:S808-S808.
40. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12:1.
41. Strangfeld A, Pattloch D, Herzer P, et al. risk of cancer recurrence or new tumors in RA patients with prior malignancies treated with various biologic agents. Arthritis Rheum. 2013;65:S342-S342.
42. Watson KD, Dixon WG, Hyrich KL, et al. Influence of antitnf therapy and previous malignancy on cancer incidence in patients with Rheumatoid Arthritis (RA): results from the BSR biologics register (BSRBR). Rheumatology. 2006;45:I10-I10.
43. Cordtz R, Mellemkjaer L, Glintborg B, et al. malignant progression of precancerous lesions of the uterine cervix following DMARD therapy in female arthritis patients. Arthritis Rheumatol. 2014;66:S374-S375.
44. Mercer L, Low A, Galloway J, et al. Outcome of women with previous carcinoma in situ of the cervix with respect to female genital cancer, following treatment with non-biologic dmard or anti-TNF for rheumatoid arthritis: results from the BSRBR. Rheumatology. 2012;51:77.
45. Mercer LK, Low AS, Galloway JB, et al. Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Ann Rheum Dis. 2013;72:143-144.
46. Albert C, Brocq O, Grisot C, et al. Safety of anti-TNF alpha in patients with rheumatoid arthritis (RA) and solid tumor. Ann Rheum Dis. 2007;66:162.
47. Bae SH, Lim DH, Ahn SM, et al. Safety of TNF inhibitor therapy in patients who have had a prior malignancy. Arthritis Rheumatol. 2014;66:S374-S374.
48. Bahamonde LG, Velayos FS, Katz S, et al. Factors influencing the treatment of inflammatory bowel disease in patients with cancer recurrence: pilot study. Gastroenterology. 2013;144:S408-S408.
49. Chabbert C, Adamski H, Guillet G, et al. Cutaneous melanoma in patients treated with tumour necrosis factor inhibitors: a retrospective series of 15 patients. J Eur Acad Dermatol Venereol. 2014;28:1540-1544.
50. Chong BF, Wong HK. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma. Clin Exp Dermatol. 2009;34:e11-e13.
51. Engel SH, Hullar TE, Adkins DR, et al. Temporal relationship between antitumor necrosis factor-alpha antibody therapy and recrudescence of head and neck squamous cell carcinoma. Laryngoscope. 2008;118:450-452.
52. Fulchiero GJ Jr, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007;56(5 suppl):S65-S67.
53. Guerra I, Algaba A, Quintanilla E, et al. Management and course of inflammatory bowel disease patients with associated cancer. J Crohns Colitis. 2014;8:S49-S49.
54. Kuroda T, Sato H, Nakatsue T, et al. Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report. BMC Res Notes. 2014;7:229.
55. Onali S, Petruzziello C, Ascolani M, et al. Thiopurines and anti-TNFS in patients with inflammatory bowel disease and a positive history of cancer. J Crohns Colitis. 2015;9:S215-S215.
56. Pai S, Rosenstein ED, Kramer N. Etanercept therapy for psoriatic arthritis in the presence of recurrent non-Hodgkin lymphoma. J Clin Rheumatol. 2012;18:301-303.
57. Poullenot F, Seksik P, Beaugerie L, et al. Risk of incident cancer in patients with inflammatory bowel disease starting anti-TNF therapy while having prior malignancy within past 5 years (GETAID survey). J Crohns Colitis. 2014;8:S214-S214.
58. Raffeiner BMA, Botsios C, Sfriso P, et al. Occurence of malignancies during TNF alpha blocker therapy in rheumatoid arthritis patients of northeast italy with and without prior malignancy. Ann Rheum Dis. 2010;69(suppl 3).
59. Rajca S, Seksik P, Bourrier A, et al. Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. J Crohns Colitis. 2014;8:819-824.
60. Velloso M, Montero SR, Mayordomo L, et al. Etanercept therapy for RA patients with breast cancer. Ann Rheum Dis. 2007;66:181.
61. Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416-1423.
62. Algaba A, Guerra I, Marin-Jimenez I, et al. Incidence, management, and course of cancer in patients with inflammatory bowel disease. J Crohns Colitis. 2015;9:326-333.
63. Axelrad J, Bernheim O, Colombel JF, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and antitumor necrosis factor agents. Clin Gastroenterol Hepatol. 2015;14:58-64.
64. Dreyer L, Mellemkjaer L, Hansen IMJ, et al. impact of biological treatment on overall mortality and on incidence of second cancers in arthritis patients - a follow-up study from the Danish DANBIO registry. Arthritis Rheum. 2013;65:S442-S443.
65. Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2012;71:869-874.
66. Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013;346:f1939.
67. Phillips CZAL, McDonald JR, Eisen SA, et al. Effect of Disease-Modifying Anti-Rheumatic Drug (DMARD) exposure on head and neck cancer in a national cohort of veterans with rheumatoid arthritis. Arthritis Rheum. 2010;62:10.
68. Raaschou P, Frisell T, Askling J, et al. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014;74:1-7.
69. Scott FI, Mamtani R, Brensinger CM, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol. 2015;5:164-172.
70. Silva-Fernandez L, Lunt M, Watson KD, et al. The influence of anti-TNF or rituximab on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy. Ann Rheum Dis. 2014;73:674.
71. Beaugerie L. Management of inflammatory bowel disease patients with a cancer history. Curr Drug Targets. 2014;15: 1042-1048.
72. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617-1625.
73. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268-274.
74. Lopez A, Mounier M, Bouvier AM, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1324-1329.
75. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145:1007-15.e3.
76. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361-371.
77. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72:3666-3670.
78. Madhusudan S, Muthuramalingam SR, Braybrooke JP, et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol. 2005;23:5950-5959.
79. Glazier DB, Bahnson RR, McLeod DG, et al. Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. J Urol. 1995;154:66-68.
80. Brown ER, Charles KA, Hoare SA, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol. 2008;19:1340-1346.
81. Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006;84:1463-1472.
82. Choi SW, Stiff P, Cooke K, et al. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transplant. 2012;18:1525-1532.
83. Dixon W, Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. Arthritis Res Ther. 2006;8:111.
84. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895-1904.
85. Raaschou P, Simard JF, Neovius M, et al. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and sitespecific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum. 2011;63:1812-1822.
86. Curtis REFM, Ron E. New malignancies among cancer survivors: SEER cancer registries, 1993-2000. NIH Publ. 2006:5.
87. Schaapveld M, Aleman BM, van Eggermond AM, et al. second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015;373:2499-2511.
88. Shelton E, Laharie D, Scott FI, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and metaanalysis. Gastroenterology. 2016;151:97-109.
89. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
90. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet. 2002;359:248-252.